



18<sup>th</sup> May 2012

### **Aurobindo Pharma receives final approval for Clopidogrel Tablets**

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Clopidogrel Tablets USP 75 mg (ANDA 090540), which is being launched.

Clopidogrel Tablets USP 75 mg is the generic equivalent of Aventis US LLC (Sanofi)'s Plavix® Tablets USP 75mg. The product falls under the cardio-vascular (CVS) therapeutic category and is indicated for the prevention of atherothrombotic events in patients who have had a myocardial infarction or ischaemic stroke, or who have established peripheral arterial disease). The annual sale of the product is approximately US\$ 6.4 billion

The product has been approved out of Unit III formulations facility in Hyderabad, India

Aurobindo now has a total of 151 ANDA approvals (123 Final approvals including 1 from Aurolife Pharma LLC and 28 Tentative approvals) from USFDA

#### **About Aurobindo Pharma Limited:**

Aurobindo Pharma Limited ([www.aurobindo.com](http://www.aurobindo.com)), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

#### **For further information, please contact:**

Investor Relations  
Aurobindo Pharma Limited  
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad  
Phone: 040-66725000 / 66725401  
Email: [ir@aurobindo.com](mailto:ir@aurobindo.com)